Payment overview · 2025
General Payments
$292.77
15 reported records · 10 companies
Healthcare provider profile · identity verified
Derek Wayne White, DO
Allopathic & Osteopathic Physicians|Family Medicine · ABINGDON, VA · NPI 1619497294
Verified facts
What the public records show
CMS Open Payments records show Derek Wayne White, DO received $292.77 in general payments during 2025 across 15 reported records.
Exact Sciences Corporation accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.42 | 23.0% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $45.04 | 15.4% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.96 | 14.7% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $27.01 | 9.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $24.56 | 8.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.97 | 7.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.50 | 6.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.85 | 5.8% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.00 | 5.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.46 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $292.77 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $67.42 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $45.04 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $42.96 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $42.96 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $27.01 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 510 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 442 | 139 |
| Lisinopril | Lisinopril | 423 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 137 |
| Omeprazole | Omeprazole | 341 | 104 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 330 | 70 |
| Losartan Potassium | Losartan Potassium | 313 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 233 | 71 |
| Trazodone Hcl | Trazodone Hcl | 224 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 209 | 63 |
| Metformin Hcl | Metformin Hcl | 204 | 63 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 198 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 187 | 51 |
| Famotidine | Famotidine | 170 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 53 |
| Carvedilol | Carvedilol | 152 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 47 |
| Tramadol Hcl | Tramadol Hcl | 141 | 24 |
| Furosemide | Furosemide | 133 | 53 |
| Ondansetron Odt | Ondansetron | 128 | 35 |
| Eliquis | Apixaban | 122 | 31 |
| Lorazepam | Lorazepam | 122 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 32 |
| Montelukast Sodium | Montelukast Sodium | 115 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 112 | 19 |
| Potassium Chloride | Potassium Chloride | 105 | 35 |
| Buspirone Hcl | Buspirone Hcl | 102 | 24 |
| Allopurinol | Allopurinol | 99 | 33 |
| Metformin Hcl Er | Metformin Hcl | 99 | 33 |
| Sertraline Hcl | Sertraline Hcl | 98 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 26 |
| Alprazolam | Alprazolam | 87 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 20 |
| Clonazepam | Clonazepam | 83 | 18 |
| Ozempic | Semaglutide | 81 | 24 |
| Valsartan | Valsartan | 81 | 32 |
| Jardiance | Empagliflozin | 80 | 21 |
| Pregabalin | Pregabalin | 80 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 20 |
| Simvastatin | Simvastatin | 77 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 22 |
| Mirtazapine | Mirtazapine | 76 | 21 |
| Meloxicam | Meloxicam | 75 | 27 |
| Alendronate Sodium | Alendronate Sodium | 69 | 26 |
| Methocarbamol | Methocarbamol | 69 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 69 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 20 |
| Sucralfate | Sucralfate | 64 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 20 |
| Ibuprofen | Ibuprofen | 61 | 17 |
| Spironolactone | Spironolactone | 60 | 23 |
| Bupropion Xl | Bupropion Hcl | 59 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 21 |
| Finasteride | Finasteride | 53 | 19 |
| Prednisone | Prednisone | 52 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 17 |
| Donepezil Hcl | Donepezil Hcl | 50 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 13 |
| Atenolol | Atenolol | 48 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 14 |
| Glimepiride | Glimepiride | 45 | 14 |
| Celecoxib | Celecoxib | 43 | 14 |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 15 |
| Meclizine Hcl | Meclizine Hcl | 40 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | 11 |
| Cephalexin | Cephalexin | 38 | 23 |
| Glipizide | Glipizide | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | 16 |
| Chlorthalidone | Chlorthalidone | 37 | 15 |
| Propranolol Hcl | Propranolol Hcl | 37 | 15 |
| Aripiprazole | Aripiprazole | 36 | 13 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Fentanyl | Fentanyl | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 16 |
| Temazepam | Temazepam | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 17 |
| Trulicity | Dulaglutide | 35 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 12 |
| Mounjaro | Tirzepatide | 32 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 28 |
| Xarelto | Rivaroxaban | 29 | 12 |
| Diazepam | Diazepam | 28 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Ibu | Ibuprofen | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Acetazolamide Er | Acetazolamide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $292.77 · 15 records | Exact Sciences Corporation | ABRYSVO, CAPLYTA, Cologuard Collection Kit, FANAPT, HETLIOZ, INGREZZA, INJECTAFER, PREVNAR 20, QULIPTA, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, XYOSTED | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error